Carbamylated low-density lipoprotein induces death of endothelial cells: A link to atherosclerosis in patients with kidney disease

Kidney International

Volumn 68, Issue 1, 2005, Pages 173-178

  Ok, Ercan ^b   Basnakian, Alexei G ^b   Apostolov, Eugene O ^b   Barri, Yousri M ^b   Shah, Sudhir V ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

Carbamylated LDL; Carbamylation; End stage renal disease; Endothelial cells; Kidney; Low density lipoprotein

Indexed keywords

BROXURIDINE; HOMOCITRULLINE; LACTATE DEHYDROGENASE; LIPOCORTIN 5; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMA PROTEIN; POTASSIUM; CARBAMYL LDL; CARBAMYL-LDL;

APOPTOSIS; ARTERY MUSCLE; ARTICLE; ATHEROSCLEROSIS; CARBAMOYLATION; CELL DAMAGE; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CHRONOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HEMODIALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; MICROSCOPY; PATIENT; PRIORITY JOURNAL; ARTERIOSCLEROSIS; BLOOD; CELL CULTURE; CELL DIVISION; CHRONIC KIDNEY FAILURE; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG EFFECT; METABOLISM; PATHOLOGY; RENAL REPLACEMENT THERAPY; VASCULAR SMOOTH MUSCLE;

ARTERIOSCLEROSIS; CELL DEATH; CELL DIVISION; CELLS, CULTURED; CHOLESTEROL, LDL; CORONARY VESSELS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, LDL; MUSCLE, SMOOTH, VASCULAR; RENAL DIALYSIS;

EID: 24944550971     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00391.x     Document Type: Article

References (25)

1. LEVEY AS, CORESH J, BALK E, et al: National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Ann Intern Med 139:137-147, 2003
2. NISSENSON AR, PEREIRA BJ, COLLINS AJ, et al: Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis 37:1177-1183, 2001
3. CHADBAN SJ, BRIGANTI EM, KERR PG, et al: Prevalence of kidney damage in Australian adults: The AusDiab Kidney Study. J Am Soc Nephrol 14:8131-8138, 2003
4. SARNAK MJ, LEVEY AS, SCHOOLWERTH AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: A Statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
5. KRAUS LM, KRAUS AP: Carbamylation of amino acids and proteins in uremia. Kidney Int 78:8102-8107, 2001
6. DIMMELER S, HERMANN C, ZEIHER AM: Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis? Euro Cytokine Network 9:697, 1998
7. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 340:115, 1999
8. CHOY JC, GRANVILLE DJ, HUNT DW, et al: Endothelial cell apoptosis: Biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 33:1673-1690, 2001
9. WEISGRABER KH, INNERARITY TL, MAHLEY RW: Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem 253:9053-9062, 1978
10. NOBLE RP: Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 9:693-700, 1968
11. TREPANTER DJ, THIBERT RJ, DRAISEY TF, et al: Carbamylation of erythrocyte membrane proteins: An in vitro and in vivo study. Clin Biochem 29:347-355, 1996
12. KIM RS, LABELLA FS: Comparison of analytical methods for monitoring autoxidation profiles of authentic lipids. J Lipid Res 28:1110-1117, 1987
13. UEDA N, SHAH SV: Endonuclease-induced DNA damage and cell death in oxidant injury to renal tubular epithelial cells. J Clin Invest 90:2593-2597, 1992
14. LOREC AM, JUHET C, PAFUMI Y, et al: Determination of apolipoprotein B-48 in plasma by a competitive ELISA. Clin Chem 46:1638-1642, 2000
15. BUCALA R, VLASSARA H: Advanced glycosylation end products in diabetic renal disease: Clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition. Blood Purif 13:160-170, 1995
16. FERRETTI G, BACCHETTI T, MORONI C, et al: Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 92:351-360, 2004
17. VAN TITS L, DE GRAAF J, HAK-LEMMERS H, et al: Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab Invest 83:13-21, 2003
18. TAKENAKA T, TAKAHASHI K, KOBAYASHI T, et al: Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients. Clin Nephrol 58:33-37, 2002
19. FUTATSUYAMA M, OIWA T, KOMATSU Y: Correlation between oxidized low-density lipoprotein and other factors in patients on peritoneal dialysis. Adv Perit Dial 18:192-194, 2002
20. DAVENPORT A, JONES S, GOEL S, et al: Carbamylated hemoglobin: A potential marker for the adequacy of hemodialysis therapy in end-stage renal failure. Kidney Int 50:1344-1351, 1996
21. KUCKEL CL, LUBIT BW, LAMBOOY PK, et al: Methylisocyanate and actin polymerization: The in vitro effects of carbamylation. Biochim Biophys Acta 1162:143-148, 1993
22. INOUE CN, NAGANO I, ICHINOHASAMA R, et al: Bimodal effects of platelet-derived growth factor on rat mesangial cell proliferation and death, and the role of lysophosphatidic acid in cell survival. Clin Sci (Lond) 101:11-19, 2001
23. HORKKO S, SAVOLAINEN MJ, KERVINEN K, et al: Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int 41:1175-1181, 1992
24. HORKKO S, HUTTUNEN K, KERVINEN K, et al: Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur J Clin Invest 24:105-113, 1994
25. ROSS R, GLOMSET JA: Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180:1332-1339, 1973